Afimoxifene

Drug Profile

Afimoxifene

Alternative Names: 4-Hydroxytamoxifen; 4-Hydroxytamoxifen (afimoxifene) gel; 4-Hydroxytamoxifen gel; 4-OH tamoxifen; 4-OHT; TamoGel

Latest Information Update: 02 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Besins International
  • Developer Atossa Genetics; Besins Healthcare; BHR Pharma
  • Class Antineoplastics; Hydroxytestosterones; Non-opioid analgesics
  • Mechanism of Action Estrogen receptor antagonists; Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hyperplasia
  • Phase II Breast cancer
  • No development reported Breast pain; Gynaecomastia
  • Discontinued Keloids

Most Recent Events

  • 21 Aug 2017 Phase-III clinical trials in Hyperplasia in USA (Topical) (NCT03199963)
  • 03 Jul 2017 BHR Pharma plans a phase III trial for Hyperplasia (NCT03199963)
  • 31 May 2017 National Cancer Institute initiates enrolment in a phase IIb trial for Breast cancer in USA (Topical) (NCT02993159)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top